Kenvue Inc. $KVUE Holdings Lifted by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 18.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,773,258 shares of the company’s stock after purchasing an additional 889,163 shares during the quarter. Kenvue makes up 1.6% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 29th largest position. Mondrian Investment Partners LTD’s holdings in Kenvue were worth $99,589,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Physician Wealth Advisors Inc. grew its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Versor Investments LP grew its holdings in shares of Kenvue by 2.8% during the third quarter. Versor Investments LP now owns 26,016 shares of the company’s stock valued at $422,000 after buying an additional 716 shares in the last quarter. Philip James Wealth Mangement LLC grew its holdings in shares of Kenvue by 5.5% during the fourth quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock valued at $240,000 after buying an additional 726 shares in the last quarter. Phoenix Financial Ltd. grew its holdings in shares of Kenvue by 5.4% during the fourth quarter. Phoenix Financial Ltd. now owns 15,195 shares of the company’s stock valued at $262,000 after buying an additional 783 shares in the last quarter. Finally, Titleist Asset Management LLC grew its holdings in shares of Kenvue by 1.6% during the third quarter. Titleist Asset Management LLC now owns 50,957 shares of the company’s stock valued at $827,000 after buying an additional 796 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $23.00 to $18.00 in a report on Friday, January 30th. Canaccord Genuity Group lifted their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Finally, Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Price Performance

KVUE opened at $17.55 on Friday. The stock has a market cap of $33.69 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.33 and a beta of 0.55. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $24.00. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average price of $17.40 and a 200 day moving average price of $17.42.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.24 earnings per share. Analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be given a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.